• Circio Holding published its ESGCT presentation on the circVec platform for next-generation gene and cell therapies.
• Heart optimization increased gene expression approximately 200-fold versus conventional mRNA-based AAV, with 95% on-target specificity.
• Nonviral circVec delivery sustained spleen expression for up to six months on one dose, versus two weeks for mVec.
• T-cell-targeted delivery produced spleen signals at all tested doses with more than two months of durability.
• Capital raised in 2026 totaled €80 million to fund the next phase of research and development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Circio Holding ASA published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.